Abstract Impaired DNA damage response (DDR) may play a fundamental role in the pathogenesis of breast cancer (BC). RAD51 is a key player in DNA double-strand break repair. In this study, we aimed to assess the biological and clinical significance of RAD51 expression with relevance to different molecular classes of BC and patients' outcome. The expression of RAD51 was assessed immunohistochemically in a well-characterised annotated series (n = 1184) of earlystage invasive BC with long-term follow-up. A subset of cases of BC from patients with known BRCA1 germline mutations was included as a control group. The results were correlated with clinicopathological and molecular parameters and patients' outcome. RAD51 protein expression level was also assayed in a panel of cell lines using reverse phase protein array (RPPA). RAD51 was expressed in the nuclei (N) and cytoplasm (C) of malignant cells. Subcellular colocalisation phenotypes of RAD51 were significantly associated with clinicopathological features and patient outcome. Cytoplasmic expression (RAD51C ? ) and lack of nuclear expression (RAD51 N -) were associated with features of aggressive behaviour, including larger tumour size, high grade, lymph nodal metastasis, basal-like, and triplenegative phenotypes, together with aberrant expression of key DDR biomarkers including BRCA1. All BRCA1-mutated tumours had RAD51C
Introduction
RAD51 plays a major role in homologous recombination (HR) of DNA during double-strand break (DSB) repair. Of the various types of DNA damage that occur within a mammalian cell, DSB is recognised as the most lethal [1, 2] . Many studies have indicated a link between DSB and genomic instability and cancer [1, 3] . Repair of DSB can be achieved through one of the two overlapping pathways: HR and non-homologous end-joining (NHEJ) pathways [4] . The main difference between these two pathways lies in the requirement of a homologous DNA template during the repair process [1] . In HR, RAD51 is involved in the search for homology and strand-pairing stages of the process. Unlike other proteins involved in DNA damage repair, RAD51 forms a helical nucleoprotein filament on DNA. A single strand of DNA is coated with RAD51 to form a nucleoprotein filament that penetrates and makes pairs with a homologous region in duplex DNA, leading to the activation of strand exchange and the creation of a crossover between the juxtaposed DNA [5, 6] . Importantly, BRCA1 co-localises with RAD51 to form a complex [7, 8] . This was evidenced by the reduced formation of RAD51 after treatment with DNA-damaging agents and during HR in BRCA1 deficient cells [9] .
Moreover, previous studies have demonstrated that HR is defective in BRCA1 deficient cells [10] . RAD51 may also be required for NHEJ pathway of DSB repair interacting with the single-strand DNA-binding proteins such as BRCA2, PALB2 and RAD52 [11] . Several studies have indicated that RAD51 nuclear expression is increased in metastatic mammary carcinoma, indicating that it may play an important role in the mammary carcinogenesis [12] [13] [14] [15] . However, an increased risk of distant metastasis occurs with an increased cytoplasmic expression of RAD51 [16] , and RAD51 nuclear foci are inversely associated with tumour response to chemotherapy [17] .
The aim of this study is to investigate the expression of RAD51 in a large, well-characterised clinically and molecularly annotated series of early-stage sporadic BC using immunohistochemistry to determine the association between RAD51 and clinicopathological and molecular features and clinical outcome. A series of BRCA-mutated BC was used as a control group for tumours with deficient HR pathway. In addition, reverse phase protein assay (RPPA) was used to quantify RAD51 protein expression in cell lines representing different BC molecular classes.
Materials and methods

Study cohort
A well-characterised cohort of unselected primary operable invasive BC (n = 1184) derived from the Nottingham Tenovus primary breast carcinoma series from female patients presenting between 1989 and 1998 formed the material of this study. In addition, a group of BRCA1 germline mutation carrier (n = 18 cases) were also studied. Data relating to patients' clinicopathological features were available including patients' age, menopausal status, primary tumour size, histological tumour type, tumour grade, axillary nodal status, lymphovascular invasion and Nottingham Prognostic Index (NPI) [18, 19] . Survival data were available and prospectively maintained, including development of locoregional, distant recurrences, and breast cancer-related mortality. The median follow-up time of the sporadic BC series was 177 months (range 1-308 months) and of the BRCA1-mutated series was 93 months (range 9-274 months). Using these outcome data, BC-specific survival (BCSS) was calculated, using appropriate statistical tests, as the time (in months) from the date of primary surgery to the time of death because of BC.
Patients in these series were managed in accordance to a standard uniform protocol based on patients' and tumour characteristics; NPI and ER status, and menopausal status [19] . Patients within the excellent NPI prognostic group (score B3.4) received no adjuvant therapy, but those patients with NPI [3.4 received Tamoxifen if ER-positive (±Zoladex in case the patients were pre-menopausal). On the other hand, classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) were used if the patients were ER-negative and fit to receive chemotherapy.
Data on the following biomarkers were available: ER, progesterone receptor (PgR), HER-2, DNA damage response proteins (BRCA1, BARD1, KU70/KU80, DNAPKcs, PIAS1, and CHK1), basal cytokeratins [CK5, CK14, and CK17], and proliferation and cell cycle-associated proteins (Ki67, and P53). In this series, HER-2 was assessed using IHC (DAKO) and dual-colour chromogenic in situ hybridisation (CISH), as previously published [20] . Ki67 labelling index (Ki67LI) was assessed on full-face tumour tissue sections and was assessed as the percentage of Ki67-positive cells among a total number of 1000 malignant cells at high power magnification (9400) [20] . Supplementary Table 1 displays sources, dilution, cut-off point and pre-treatment conditions used of the antibodies of DNA damage sensing and repair markers used in this study. The staining conditions as well as data dichotomy of other markers in this study were defined, as previously described [18] [19] [20] [21] [22] . This study was approved by Nottingham Research Ethics Committee 2.
Immunohistochemistry
Immunohistochemistry was carried out using the Novolink Kit-polymer detection system (Leica, Newcastle, UK). Antigen retrieval was performed in citrate buffer solution (pH 6) by heating in a microwave for 20 min. Anti-RAD51 primary antibody was used (clone Ab88572, Abcam Ltd., Cambridge, UK) optimally diluted at 1:70 and incubated for 60 min at room temperature. Freshly prepared 3-3 0 diaminobenzidine tetrahydrochloride (Novolink DAB substrate buffer plus) was used as a chromogen for reaction visualisation. The stained TMA sections were counterstained with haematoxylin for 6 min [22] . 
Scoring of RAD51 immunohistochemical staining
High-resolution digital images (Nanozoomer; Hamamatsu Photonics, Welwyn Garden City, UK) scanned at 920 magnification was used to facilitate the visual scoring of the TMA cores via web-based interface (Distiller; Slidepath, Ltd., Dublin, Ireland). Only immunostaining of invasive BC cells within the tissue cores was considered as positive. The semi-quantitative modified histochemical score (H-score) was used to assess RAD51 staining [23] . Thirty percent of the stained RAD51 TMA cores were rescored by another observer, and statistical agreement between the two scores was calculated using inter-rater Kappa statistic (Table 1) .
Antibody specificity and reverse phase protein microarray (RPPA)
To test the specificity of the used antibody and to confirm the expression of RAD51 in specific BC cell lines corresponding to molecular classes of BC, Western blotting and RPPA were performed, as previously described [18, 24, 25] . Four different cell lines were used: luminal ]. ANOVA test was used for each marker within the classes Table 2 Associations between RAD51 co-localisation expression groups and DNA damage repair biomarkers For Western blotting, the anti-RAD51 primary antibody (clone Ab88572, Abcam Ltd., Cambridge, UK) was used (1:1000, and incubated for 1 h at room temperature). The reaction was developed using Enhanced Chemiluminescence substrate (GE Healthcare Life Sciences, Buckinghamshire, UK). For RPPA, RAD51 was used (1:100 in a reducing background DAKO antibody diluent). In addition, GAPDH (BioLegend, 1:250 in the same diluent) was used as a housekeeping protein to control protein loading. Protein signals were determined with background subtraction and normalisation to the internal housekeeping protein using RPPanalyzer, a module within the R statistical language on the CRAN (http://cran.r-project.org/) [26] .
Statistical analysis
All statistical analyses were performed using SPSS 21.0 statistical software (SPPS Inc., Chicago, IL, USA). For optimal RAD51 cut-off point determination, X-tile bioinformatics software was used (version 3.6.1, 2003-2005, Yale University, USA) [27] . Correlations of categorical variables were carried out with Chi-Squared test (x 2 ). Oneway ANOVA was applied to compare the level of RAD51 expression among different BC classes for IHC and RPPA data, with pairwise differences assessment using the post hoc test. Associations with patients' outcome were assessed using Kaplan-Meier curves and log-rank test. A twosided P value of \0.01 was considered statistically significant.
Results
Expression of RAD51 in invasive breast cancer
The specificity of RAD51 antibody was confirmed by Western blotting as demonstrated by single band at the correct protein size (Fig. 1, panel A) . Using immunohistochemistry, RAD51 expression was localised to nuclei and cytoplasm of the malignant cells with no membrane staining (Fig. 1, panel II) . For analytical purposes, RAD51 H-score was categorised using X-tile software. The cut-off points used for nuclear RAD51 expression positive was C10 H-score and for RAD51 cytoplasmic expression was C80 H-score (Table 1) . Expression of RAD51 varied among BC molecular classes based on the status of BRCA1 and hormone receptor expression (Fig. 1, panel III) . There was a strong expression of nuclear RAD51 in the sporadic ER-positive and BRCA1-positive class compared to ERnegative and BRCA1-negative sporadic and hereditary BC classes (P \ 0.0001 and P = 0.0001, respectively).
Association between RAD51 and clinicopathological features
Subcellular expression of RAD51 was distinctively associated with clinicopathological features: cytoplasmic expression was positively associated, while nuclear expression was negatively associated with features characteristics of aggressive behaviour. Therefore, further analyses were carried out following classification of BC based on subcellular co-localisation into four groups: double-negative expression group [cytoplasmic (C) and nuclear (N) negative, (C -/N -), 6. No number, C cytoplasmic, and N nuclear expression significant associations with poor prognostic features such as larger tumour size, higher grade with nuclear pleomorphism and frequent mitotic figures (Table 1 , P \ 0.0001). It was observed that up to 75 % of RAD51 C ? /N -group were of large tumour size ([2 cm) and of grade 3 tumours. Table 2 summarises the associations between RAD51 subcellular co-localisation groups and other key DNA damage repair markers. The RAD51C
Association of RAD51 expression and expression of other biomarkers
? /N -phenotype showed significant association with the lack of nuclear and positive cytoplasmic expression of DNA-DSB biomarkers, BRCA1, cH2AX, CHK1 and MTA1, cytoplasmic expression of BARD1 and SMC6L1 and expression of CHK2, ATM, PTEN, the BRCA1 inhibitor ID4 and the NHEJ biomarkers KU70/KU80 and DNA-PKcs regardless of their subcellular localisation.
The association between RAD51 subcellular localisation combinatorial groups and other tissue biomarkers is summarised in Table 3 , where RAD51C
? /N -subgroup showed significant association with lack of hormone receptor (ER -and PgR -), triple-negative and basal-like (BLBC ? ) phenotypes, Ck5/6?, and high Ki67LI (P \ 0.0001). In addition, RAD51 showed significant association with the cell cycle progression/arrest regulator markers P53 and P27 (P \ 0.0001). Furthermore, there was N number of cases, C cytoplasmic, N nuclear expression, ER estrogen receptor, PgR Progesterone receptor, triple negative (ER-, PgR-and HER2-). BLBC basal-like breast cancer defined as triple negative and positive expression of CK5 and/or CK14 and/or CK17. The cut-off points of positivity were the same as previously published [21] Breast Cancer Res Treat (2016) 
Relationship between RAD51 and patient outcome
Negative nuclear expression of RAD51 demonstrated significantly shorter BCSS (P \ 0.01) with a 67 % 10-year survival rate compared to 82 % in the RAD51 nuclear positive cases, Fig. 2a . Cytoplasmic expression (RAD51C ? ) showed a trend for shorter BCSS (P = 0.02; Fig. 2b) . Furthermore, the RAD51C ? /N -phenotype had the shortest BCSS, in comparison to other subcellular combinations ( Fig. 2c; RAD51C ? /N ? , RAD51C -/N -and RAD51C -/N ? , P \ 0.01). In regards to chemotherapy, patients with RAD51 N ? tumours who did not receive adjuvant chemotherapy showed the best BCSS (P = 0.02), whereas the other groups were not significantly different from each other, Fig. 3 . Within the primary invasive BC series, cox proportional hazard regression analyses for predictors of BCSS showed that RAD51 N? was an independent predictor of longer BCSS (P \ 0.01, hazard ratio (HR), 0.73, 95 % confidence interval (CI) 0.56-0.96). However, the RAD51 nucleocytoplasmic expression groups showed non-significant association with survival (P = 0.08, HR = 1.18, 95 % CI 0.98-1.42), Table 4 .
Discussion
The mechanisms of DNA damage repair play a crucial role in the maintenance of DNA integrity to ensure high-fidelity transmission of genetic information. Therefore, inability to respond or repair DNA damage leads to genetic instability Fig. 2 The association between Rad51 and BCSS. 0 negative and 1 positive expression of Rad51. Where n nuclear expression and c cytoplasmic expression of Rad51 and N; number of cases. Only patients who died from breast cancer were considered. a Association between nuclear expression of Rad51 and BCSS, whereas b association between cytoplasmic Rad51 and BCSS. c Co-expression of nuclear and cytoplasmic of Rad51 and its association with BCSS and enhancement of cancer development [1, 2] . The deficiencies in HR pathway, with BRCA1 and RAD51 as key markers, result in a marked increase in the risk of early onset of breast, ovarian and other cancers [28] . RAD51 is essential for genetic recombination and DNA repair as it has the ability to promote joint molecule formation and DNA strand exchange between homologous DNA molecules [6, 29, 30] . RAD51 binds to DNA forming highly ordered nucleoprotein filaments in which the DNA is encased within a protein sheath [31] .
In this study, the role of RAD51, with particular attention to DDR and patients' outcome, was evaluated using immunohistochemistry in a large clinically annotated series of unselected early-stage sporadic BC cases and a small cohort of BRCA1 germline mutation BC cases. Our results showed that the expression of RAD51 is both nuclear and cytoplasmic and it varies among BC molecular classes based on the status of BRCA1 and hormone receptor expression with low nuclear expression observed in BRCA1-associated tumours and in sporadic tumours lacking ER and BRCA1 expression. Low levels of nuclear RAD51 were associated with established poor prognostic factors, such as high histological grade, TN phenotype and shorter patients' survival; findings were reported by other investigators [32] .
Our results also indicate that tumours lacking nuclear RAD51 overexpress other proteins involved in the alternative DDR pathways including NHEJ as supported by the high level of expression of NHEJ proteins KU70/KU80 and DNA-PKcs. Consistent with a previous study [33] , the IHC results of RAD51 in our series of BC confirmed a direct relationship between high cytoplasmic RAD51 expression and TN status, while the opposite was observed with RAD51 nuclear expression. This finding suggests the possible role of steroid hormone receptors in the regulation of RAD51 [34] . Pedram and co-workers reported an inhibition of ATR signalling by oestradiol (E2), which produced a delay in the formation of RAD51 nuclear foci following UV-irradiation [35] . Overall, the absence of steroid hormone receptors may be a surrogate marker of E2/ER signalling, which may directly influence the DNA-DSB repair pathway [36, 37] .
Interestingly, in the results presented herein, a comparison of the RAD51 nuclear and cytoplasmic expression arising within BRCA1 mutation carriers showed high levels of cytoplasmic RAD51. This supports the hypothesis that nuclear levels of RAD51 may be lower due to the mutation of BRCA1, which might inhibit the protein transfer into the nucleus. This observation has previously been reported in prostate cancer [38] . RAD51 is similar to other DDR proteins where its cytoplasmic sequestration seems to represent lack of functional phenotype [39] . Our findings demonstrate the importance of the nucleocytoplasmic transport protein KPNA2 on the subcellular localisation of RAD51. High level of KPNA2 nuclear expression is associated with cytoplasmic localisation of RAD51. Although KPNA2 is a nuclear import protein [40, 41] , high nuclear accumulation of KPNA2 leads to cytoplasmic retention of nuclear localisation sequence (NLS)-containing cargo proteins due to defective import [42] . RAD51 cyto-nuclear transport is an essential aspect of the cellular response to DNA damage [43] . Nuclear localisation of KPNA2 in cancer is thought to be due to cellular stress, and some authors have demonstrated that the nuclear retention of KPNA2 in response to cellular stress suppresses the nuclear import [44] .
In cancer cell lines with a HR defect, such as BRCA1 or BRCA2 loss, the cells are unable to stimulate foci of RAD51 following DNA damage [32, 45] leading to a functional readout of a defect in HR. in this study, for quantitative expression of RAD51 in relation to molecular class of BC and other DDR proteins, RAD51 was assessed in different BC cell lines using RPPA. The results obtained by IHC and RPPA revealed lower levels of RAD51 in the HeLa BRCA1 cell line (BRCA1 deficient), or known BRCA1-mutated BC cases/ER-BC, than the control HeLa BRCA1 cell line (BRCA1 proficient) or sporadic BC showing positive BRCA1 and ER. This finding may propose a defect in the HR pathway in BRCA1-mutated cases/ The link between loss of PTEN and defective DNA-DSB repair has been previously studied. PTEN works on chromatin and controls the expression of RAD51, which usually decreases the incidence of spontaneous DSBs. Accordingly, PTEN deficient cells have defective DNA-DSB repair, possibly due to loss or down regulation of RAD51, in addition to loss of PTEN at centromeres [46] . In the present study, RAD51C
? /N -expression localisation was associated with loss of PTEN. These findings may indicate a role for PTEN involvement in HR of DNA repair.
Both CHK1 and CHK2 are essential kinases for the repair of DNA and are important in the recruitment of the functional associations between BRCA1 and RAD51 proteins; thus, they increase the HR-mediated repair of stalled replication forks [47] . CHK1 phosphorylates RAD51 and other proteins, such as FANCD2, in order to promote the repair pathways of DNA [48] . In this study, there was a significant positive association between CHK1 N, but not cytoplasmic expression, and RAD51 N expression. Moreover, nuclear CHK2 expression showed a positive association with the cytoplasmic and a negative association with the RAD51 nuclear expression. Cases exhibiting low nuclear CHK1 and high cytoplasmic expression or CHK2 might hypothetically have a deficiency in response to DNA damage, leading to a further aggressive tumour. Bahassi et al. investigated the functional associations between BRCA2 and RAD51 in response to DNA damage and its regulation by CHK1 or CHK2. In UV-treated cells, the CHK1 depletion from cells using siRNA produces a complete loss of RAD51 localisation to nuclear foci with subsequent replication block [49] . Conversely, cells of truncated and non-functional CHK2 have no obvious defect in localisation at the foci of RAD51, suggesting that CHK1 is a key member in controlling BRCA2-RAD51 interaction in response to replication block. Cells lacking CHK2 display a noticeable impairment in RAD51 localisation instantly after DNA-DSB, as induced by ionising radiation treatment [49] .
Nuclear overexpression of RAD51 protein in patients treated with adjuvant chemotherapy was associated with a shorter BCSS compared to those who did not receive chemotherapy. In line with these findings, it has been reported that the formation of RAD51 foci in response to DNA damage is related to the response to neoadjuvant anthracycline-based chemotherapy in BC [32] . This could be explained by the ability of the chemotherapeutic agents to bind to DNA-producing cross-links, in addition to triggering cell death through the induction of DSBs [50] . This could suggest that a defect in the HR pathway may be responsible for failure to repair damage caused by these agents, with subsequent activation of the error-prone backup NHEJ pathways to repair DNA [51] [52] [53] .
Conclusions
The significant associations between RAD51 subcellular localisation and clinicopathological and molecular features and outcome suggest that the cyto-nuclear trafficking of DDR proteins might play a role in BC development and progression. Differential expression of RAD51 based on hormone receptor and BRCA1 status as observed using IHC is noted in both sporadic and hereditary BC and is demonstrated on cell lines using RPPA. Investigating large panel of biomarkers involved in the different pathways of DDR is likely to improve our understanding of the complex DDR mechanisms in BC.
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